Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Jeffrey W. Clark"'
Autor:
Florence K. Keane, Jeffrey W. Clark, Jill N. Allen, Theodore S. Hong, Keith D. Lillemoe, Cristina R. Ferrone, Jennifer Y. Wo, Lawrence S. Blaszkowsky, Nora Horick, Jon M Harrison, Motaz Qadan, Carlos Fernandez-del Castillo
Publikováno v:
Annals of Surgical Oncology. 27:1400-1406
To define short-term and long-term outcomes of IORT for the management of BR/LA PDAC in the era of modern neoadjuvant therapy (NAT). In the era of neoadjuvant FOLFIRINOX, many patients with borderline resectable/locally advanced (BR/LA) pancreatic du
Autor:
Yoshifumi, Noda, Nisanard, Pisuchpen, Nathaniel D, Mercaldo, Yurie, Sekigami, Theodoros, Michelakos, Anushri, Parakh, Jennifer Y, Wo, Motaz, Qadan, Cristina, Ferrone, Keith D, Lillemoe, David P, Ryan, Jeffrey W, Clark, Carlos, Fernandez-Del Castillo, Theodore S, Hong, Avinash R, Kambadakone
Publikováno v:
European radiology. 32(4)
To derive a CT-based scoring system incorporating arterial involvement and resectability status to predict R0 resection in patients with pancreatic ductal adenocarcinoma (PDAC) undergoing neoadjuvant chemoradiation therapy (CRT).This retrospective st
Autor:
Robin Striar, Colin D. Weekes, Carlos Fernandez-del Castillo, Onofrio A. Catalano, Susanna I. Lee, Jeffrey W. Clark, Cristina R. Ferrone, David P. Ryan, Theodore S. Hong, Mark Vangel, Lina Garcia Cañamaque, Lawrence S. Blaszkowsky, Felipe S. Furtado, David Groshar, David A. Rosman, Motaz Qadan, Lale Umutlu
Imaging is central to the diagnosis and management of Pancreatic Ductal Adenocarcinoma (PDAC). This study evaluated if positron emission tomography (PET)/magnetic resonance imaging (MRI) elicited treatment modifications in PDAC when compared to stand
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78b5a2594f63785a1712d835be5dcfec
https://www.ncbi.nlm.nih.gov/pubmed/33415677
https://www.ncbi.nlm.nih.gov/pubmed/33415677
Autor:
Jill N. Allen, Carlos Fernandez-del Castillo, Jennifer Y. Wo, Motaz Qadan, Keith D. Lillemoe, Vikram Deshpande, Colin D. Weekes, Cristina R. Ferrone, David P. Ryan, Onofrio A. Catalano, Akhil Chawla, Janet E. Murphy, Jeffrey W. Clark, Theodore S. Hong, David T. Ting, Aparna Raj Parikh
Publikováno v:
Annals of surgery. 276(5)
Objective The objective of this study was to characterize the patterns of first recurrence after curative-intent resection for pancreatic adenocarcinoma (PDAC). Summary background data We evaluated the first site of recurrence after neoadjuvant treat
Autor:
Aparna R, Parikh, Annamaria, Szabolcs, Jill N, Allen, Jeffrey W, Clark, Jennifer Y, Wo, Michael, Raabe, Hannah, Thel, David, Hoyos, Arnav, Mehta, Sanya, Arshad, David J, Lieb, Lorraine C, Drapek, Lawrence S, Blaszkowsky, Bruce J, Giantonio, Colin D, Weekes, Andrew X, Zhu, Lipika, Goyal, Ryan D, Nipp, Jon S, Dubois, Emily E, Van Seventer, Bronwen E, Foreman, Lauren E, Matlack, Leilana, Ly, Jessica A, Meurer, Nir, Hacohen, David P, Ryan, Beow Y, Yeap, Ryan B, Corcoran, Benjamin D, Greenbaum, David T, Ting, Theodore S, Hong
Publikováno v:
Nature cancer. 2(11)
Overcoming intrinsic resistance to immune checkpoint blockade for microsatellite stable (MSS) colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC) remains challenging. We conducted a single-arm, non-randomized, phase II trial (NCT03104
Autor:
Theodoros, Michelakos, Yurie, Sekigami, Filippos, Kontos, Carlos, Fernández-Del Castillo, Motaz, Qadan, Vikram, Deshpande, David T, Ting, Jeffrey W, Clark, Colin D, Weekes, Aparna, Parikh, David P, Ryan, Jennifer Y, Wo, Theodore S, Hong, Jill N, Allen, Onofrio, Catalano, Andrew L, Warshaw, Keith D, Lillemoe, Cristina R, Ferrone
Publikováno v:
Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract. 25(11)
Dynamic survival data based on time already survived are lacking for resected borderline resectable/locally advanced (BR/LA) pancreatic ductal adenocarcinoma (PDAC) patients who received total neoadjuvant therapy (TNT) with FOLFIRINOX followed by che
Autor:
Theodore S. Hong, Andrew L. Warshaw, Colin D. Weekes, Marta Sandini, Markus W. Büchler, David P. Ryan, Keith D. Lillemoe, Oliver Strobel, Jeffrey W. Clark, Carlos Fernandez-del Castillo, Maximilian Weniger, Max Heckler, Mari Mino-Kenudson, Jennifer Y. Wo, Thomas Hank, Motaz Qadan, Ulf Hinz, Jon M Harrison, Thilo Hackert, Cristina R. Ferrone, Ulla Klaiber
Publikováno v:
Annals of surgery. 275(2)
OBJECTIVE To build a prognostic score for patients with primary chemotherapy undergoing surgery for pancreatic cancer based on pathological parameters and preoperative Carbohydrate antigen 19-9 (CA19-9) levels. BACKGROUND Prognostic stratification af
Autor:
Sebastian K S, Begg, David J, Birnbaum, Jeffrey W, Clark, Mari, Mino-Kenudson, Ulrich F, Wellner, Oliver, Schilling, Keith D, Lillemoe, Andrew L, Warshaw, Carlos FernÁndez-Del, Castillo, Andrew S, Liss
Publikováno v:
Anticancer research. 40(7)
FOLFIRINOX [fluorouracil (5-FU), irinotecan, oxaliplatin] and gemcitabine plus nab-paclitaxel are standard treatments for patients with pancreatic ductal adenocarcinoma (PDAC). Despite efficacy rates of less than 32%, evidence is lacking to guide the
Autor:
Carlos Fernandez-del Castillo, Jill N. Allen, David P. Ryan, Keith D. Lillemoe, Jason E. Faris, Jennifer Y. Wo, Cristina R. Ferrone, Jeffrey W. Clark, Ryan D. Nipp, Lorraine N. Drapek, Theodore S. Hong, Andrzej Niemierko, Andrew X. Zhu, Eunice L. Kwak, Janet E. Murphy, Lawrence S. Blaszkowsky
Publikováno v:
American Journal of Clinical Oncology. 41:656-661
We reviewed our experience involving patients with borderline resectable or locally advanced pancreatic cancer, treated with the dose-painted (DP) boost technique to regions of vessel involvement which preclude upfront surgical resection. We evaluate
Autor:
Carlos Fernandez-del Castillo, Jennifer Y. Wo, Theodore S. Hong, Keith D. Lillemoe, Jill N. Allen, Cristina R. Ferrone, Florence K. Keane, Lawrence S. Blaszkowsky, David P. Ryan, Eunice L. Kwak, Jeffrey W. Clark
Publikováno v:
American Journal of Clinical Oncology. 41:607-612
Improved outcomes with FOLFIRINOX or gemcitabine with nab-paclitaxel in the treatment of metastatic pancreatic adenocarcinoma (PDAC) have prompted incorporation of these regimens into neoadjuvant treatment of locally advanced unresectable PDAC. Where